Khairnar Amit, Marchand Fabien, Vidal Aurélien, Etienne Monique, Miladi Imen, Auzeloux Philippe, Cachin Florent, Eschalier Alain, Chezal Jean-Michel, Ardid Denis, Miot-Noirault Elisabeth
Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Clermont-Ferrand, France INSERM, U 990, Clermont-Ferrand, France Clermont Université, Université d'Auvergne, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France INSERM U1107 NEURO-DOL, Clermont-Ferrand, France; and.
Clermont Université, Université d'Auvergne, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France INSERM U1107 NEURO-DOL, Clermont-Ferrand, France; and.
J Nucl Med. 2015 May;56(5):798-804. doi: 10.2967/jnumed.114.151415. Epub 2015 Apr 3.
This study determined, using the intraarticular complete Freund adjuvant arthritis mice model, whether the radiotracer (99m)Tc-N-(triethylammonium)-3-propyl-[15]ane-N5 ((99m)Tc-NTP 15-5) targeting proteoglycans has a pathophysiologic validity for in vivo imaging of rheumatoid arthritis (RA) and its response to chronic nonsteroidal antiinflammatory drugs.
We investigated the time course of cartilage remodeling by (99m)Tc-NTP 15-5 scintigraphy, bone damages by (99m)Tc-hydroxymethylene diphosphonate imaging, inflammation by (18)F-FDG PET, and joint proteoglycan content and pain behavior in animals, without and with meloxicam treatment. Paw circumference, thermal pain behavior, and histology as well as proteoglycan content of the whole joint were determined.
(99m)Tc-NTP 15-5 showed specific tracer accumulation within RA joints, with a significant increase in scintigraphic ratio observed in RA versus shams from day 3 to day 28. (18)F-FDG evidenced uptake in RA joints from day 15 to day 29. Animals treated with meloxicam (5 mg/kg) exhibited a dose-dependent decrease in both (99m)Tc-NTP 15-5 and (18)F-FDG uptake ratios versus saline-treated animals. (99m)Tc-hydroxymethylene diphosphonate bone scans were only positive at day 14 in RA versus shams, with a significant effect of meloxicam. An increase in proteoglycans of RA joint and thermal pain behavior were observed and were dose-dependently reduced by meloxicam.
These experimental results bring data in favor of the (99m)Tc-NTP 15-5 radiotracer for assessing, in vivo, cartilage remodeling in RA that could be used to monitor therapy.
本研究使用关节内完全弗氏佐剂性关节炎小鼠模型,确定靶向蛋白聚糖的放射性示踪剂(99m)Tc-N-(三乙铵)-3-丙基-[15]环十五胺-N5((99m)Tc-NTP 15-5)对类风湿性关节炎(RA)的体内成像及其对慢性非甾体抗炎药反应是否具有病理生理有效性。
我们通过(99m)Tc-NTP 15-5闪烁扫描研究软骨重塑的时间进程,通过(99m)Tc-羟亚甲基二膦酸盐成像研究骨损伤,通过(18)F-FDG PET研究炎症,并在有和没有美洛昔康治疗的动物中研究关节蛋白聚糖含量和疼痛行为。测定爪周长、热痛行为、组织学以及整个关节的蛋白聚糖含量。
(99m)Tc-NTP 15-5在RA关节内显示出特异性示踪剂聚集,从第3天到第28天,RA组与假手术组相比,闪烁扫描比值显著增加。(18)F-FDG显示从第15天到第29天在RA关节中有摄取。与盐水处理的动物相比,用美洛昔康(5mg/kg)治疗的动物(99m)Tc-NTP 15-5和(18)F-FDG摄取率均呈剂量依赖性降低。(99m)Tc-羟亚甲基二膦酸盐骨扫描仅在RA组第14天与假手术组相比呈阳性,美洛昔康有显著作用。观察到RA关节蛋白聚糖增加和热痛行为,美洛昔康使其呈剂量依赖性降低。
这些实验结果提供的数据支持(99m)Tc-NTP 15-5放射性示踪剂用于体内评估RA中的软骨重塑,可用于监测治疗。